Genesis Shareholders OK Spinout of Company ssRNAi Assets into New Firm
October 29, 2009
Genesis Shareholders OK Spinout of Company ssRNAi Assets into New Firm
As reported by RNAi News earlier this month, the long-struggling Genesis recently received a commitment from Japanese biotech firm MediBic Group to invest up to NZ$1 million ($750,000) in the planned subsidiary, Solirna BioSciences.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genesis Research and Development Proposes Stock Purchase Plan to Fund ssRNAi Subsidiary
February 18, 2010 / Gene Silencing News - As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary
October 15, 2009 / Gene Silencing News - Genesis Research and Development Halts Operations Amid Cash Shortfall
May 6, 2010 / Gene Silencing News - Genesis R&D Inks Deal to Sell 7.4M Shares of Stock
June 17, 2010 / Gene Silencing News - Genesis Receives Funding Commitment for New Subsidiary, Prepares New Share-Purchase Plan
July 9, 2009 / Gene Silencing News